CYCN
Price
$3.50
Change
-$0.00 (-0.00%)
Updated
Jul 30 closing price
Capitalization
15.16M
Intraday BUY SELL Signals
ELAB
Price
$0.95
Change
+$0.07 (+7.95%)
Updated
Jul 30 closing price
Capitalization
4.31M
Intraday BUY SELL Signals
Interact to see
Advertisement

CYCN vs ELAB

CYCN vs ELAB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CYCN vs. ELAB commentary
Jul 31, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYCN is a Buy and ELAB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 31, 2026
Stock price -- (CYCN: $3.50 vs. ELAB: $0.88)
Brand notoriety: CYCN and ELAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYCN: 24% vs. ELAB: 10%
Market capitalization -- CYCN: $15.16M vs. ELAB: $4.31M
CYCN [@Biotechnology] is valued at $15.16M. ELAB’s [@Biotechnology] market capitalization is $4.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $122.26B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYCN’s FA Score shows that 1 FA rating(s) are green whileELAB’s FA Score has 1 green FA rating(s).

  • CYCN’s FA Score: 1 green, 4 red.
  • ELAB’s FA Score: 1 green, 4 red.
According to our system of comparison, CYCN is a better buy in the long-term than ELAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYCN’s TA Score shows that 2 TA indicator(s) are bullish while ELAB’s TA Score has 4 bullish TA indicator(s).

  • CYCN’s TA Score: 2 bullish, 5 bearish.
  • ELAB’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, ELAB is a better buy in the short-term than CYCN.

Price Growth

CYCN (@Biotechnology) experienced а -3.58% price change this week, while ELAB (@Biotechnology) price change was -13.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.97%. For the same industry, the average monthly price growth was -7.38%, and the average quarterly price growth was +2131.54%.

Industries' Descriptions

@Biotechnology (-1.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYCN($15.2M) has a higher market cap than ELAB($4.31M). CYCN YTD gains are higher at: 175.591 vs. ELAB (-97.523). CYCN has higher annual earnings (EBITDA): -6.73M vs. ELAB (-10.17M). ELAB has more cash in the bank: 15.1M vs. CYCN (2.82M). CYCN has less debt than ELAB: CYCN (0) vs ELAB (7.96M). CYCN has higher revenues than ELAB: CYCN (1.99M) vs ELAB (1.27M).
CYCNELABCYCN / ELAB
Capitalization15.2M4.31M353%
EBITDA-6.73M-10.17M66%
Gain YTD175.591-97.523-180%
P/E RatioN/A0.00-
Revenue1.99M1.27M157%
Total Cash2.82M15.1M19%
Total Debt07.96M-
FUNDAMENTALS RATINGS
CYCN: Fundamental Ratings
CYCN
OUTLOOK RATING
1..100
78
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
27

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CYCNELAB
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CYCN
Daily Signal:
Gain/Loss:
ELAB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NEXN10.560.10
+0.96%
Nexxen International Ltd
ENSC0.25N/A
+0.72%
Ensysce Biosciences
BEKE16.670.02
+0.12%
KE Holdings
HTGC15.97-0.27
-1.66%
Hercules Capital
VRCA5.18-0.22
-4.07%
Verrica Pharmaceuticals Inc

CYCN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCN has been loosely correlated with HRTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCN jumps, then HRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCN
1D Price
Change %
CYCN100%
N/A
HRTX - CYCN
42%
Loosely correlated
+1.56%
ELAB - CYCN
40%
Loosely correlated
-6.96%
BLRX - CYCN
39%
Loosely correlated
-1.75%
AGEN - CYCN
32%
Poorly correlated
+0.45%
GDTC - CYCN
30%
Poorly correlated
+4.48%
More

ELAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAB has been loosely correlated with LPCN. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAB jumps, then LPCN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAB
1D Price
Change %
ELAB100%
-6.96%
LPCN - ELAB
42%
Loosely correlated
-3.27%
CYCN - ELAB
40%
Loosely correlated
N/A
INO - ELAB
26%
Poorly correlated
+0.97%
LXRX - ELAB
25%
Poorly correlated
-0.85%
HURA - ELAB
25%
Poorly correlated
-4.23%
More